Shaklee Obtains Exclusive License for Liquid BioCell Collagen from BioCell Technology
MIAMI, July 21, 2025 Shaklee Corporation, Liquid Collagen Acquisition, LLC and BioCell Technology, LLC are pleased to announce an exclusive licensing agreement for Liquid BioCell® Collagen. Liquid BioCell® Collagen is a patented, multi-component nutritional ingredient designed to support skin, joint, and connective tissue health.
Shaklee, the pioneer of the nutrition supplement industry, sought the exclusive license to ensure the best-selling product could continue to be available to its consumers.
'BioCell Technology, LLC congratulates Shaklee Corporation and Liquid Collagen Acquisition, LLC on being the winning bidder for the assets of Modere. The BioCell Technology, LLC team is proud and excited to work with Shaklee Corporation and Liquid Collagen Acquisition, LLC as its exclusive licensee to bring Liquid BioCell® Collagen to the world.'
Roger Barnett, Chairman and CEO, Shaklee states 'At Shaklee, our mission has always been to help people live healthier, longer, and more fulfilled lives. By bringing this groundbreaking, clinically validated collagen technology into our Shaklee family, we're not just adding a product—we're expanding our promise to support wellness at every age and stage of life.'
The licensing agreement is in effect immediately. All products will be available to purchase through Shaklee's network of ambassadors and on Shaklee.com.
About Shaklee
Shaklee is a leading wellness company founded by Dr. Shaklee, who invented the first multivitamin in the US more than 100 years ago. As a pioneer in sustainability, Shaklee was the first company in the world to fully offset its carbon emissions and have a net zero impact on our planet. Shaklee products are backed by over 110 clinical studies proving safety and efficacy and are marketed through more than 2 million members and ambassadors in North America and Asia. With a complete wellness portfolio, Shaklee is committed to providing consumers with the products and support they need to look, feel, and live younger longer. For more information, visit www.shaklee.com, follow @shakleehq on Instagram, or like us on Facebook
About BioCell Technology, LLC
BioCell Technology, LLC is an award-winning research, product development, branding, and marketing company that manufactures innovative, science-based ingredients that have applications in dietary supplements, functional foods, and cosmetics. The company licenses its branded ingredients to leading consumer packaged goods companies for use in their finished products. For more information, visit www.BioCellTechnology.com.
View original content to download multimedia: https://www.prnewswire.com/news-releases/shaklee-obtains-exclusive-license-for-liquid-biocell-collagen-from-biocell-technology-302509818.html
SOURCE SHAKLEE CORPORATION
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a minute ago
- Yahoo
Lawmakers Press FDA to Target Knockoff Weight-Loss Drugs
(Bloomberg) -- Dozens of lawmakers are urging US health regulators to crack down on the booming market for knockoff weight-loss drugs amid mounting concerns over their potential safety risks. Trump Awards $1.26 Billion Contract to Build Biggest Immigrant Detention Center in US The High Costs of Trump's 'Big Beautiful' New Car Loan Deduction Can This Bridge Ease the Troubled US-Canadian Relationship? Salt Lake City Turns Winter Olympic Bid Into Statewide Bond Boom Trump Administration Sues NYC Over Sanctuary City Policy On Friday, a group of more than 80 bipartisan lawmakers asked the US Food and Drug Administration to stop counterfeit and copycat versions of GLP-1 drugs like Wegovy and Zepbound from flooding the market — a problem that emerged over the last year. 'We are concerned about recent reports revealing a surge in illegal and counterfeit anti-obesity medications,' they wrote in a letter to FDA Commissioner Marty Makary. 'Undoubtedly, illegal counterfeit medications pose an increased risk to patient safety with sometimes fatal consequences.' The group — spearheaded by Representatives Richard Hudson of North Carolina and Herb Conaway of New Jersey — asked the agency to ramp up enforcement over illegally imported weight-loss drugs. They suggested issuing warning letters and better monitoring non-compliant online retailers and so-called compounding pharmacies that sell the medicines. The lawmakers also said the FDA should work in tandem with US Customs and Border Patrol agents to stop Chinese entities from shipping unsafe weight-loss drugs into the US. They requested an update on the FDA's efforts by July 30, given the 'urgency' of the situation. A spokesperson for the FDA said the agency will work with the US Department of Health and Human Services to provide a 'complete and thorough' response to the issues raised in the lawmakers' letter. 'Any effort to undermine America's supply of safe medicines is an issue that FDA takes seriously,' the spokesperson said. 'And we are deeply committed to strengthening the oversight of imported products at US ports of entry.' In recent years, the popularity of GLP-1 drugs has led to an explosion of copycats and counterfeits made by companies seeking to capitalize on the hype. State-licensed pharmacies were temporarily allowed to make copies of the drugs during a supply shortage, but are no longer permitted to do so after Novo Nordisk A/S and Eli Lilly & Co. boosted production. Still, some pharmacies have refused to wind down their operations while others have pivoted to selling the drugs in lower doses in order to avoid regulatory scrutiny. Counterfeit drugs are made by unregistered entities typically using illegally imported ingredients. As recently as April, there continue to be instances when counterfeit Ozempic pens covertly enter the drug supply chain undetected. Some patients are also purchasing ingredients directly from online sellers in an attempt to make the drugs themselves at home. In both cases, the medications don't go through the same rigorous approval process as brand-name drugs made by Novo and Lilly. Experts worry the lack of oversight is putting patients at risk. The FDA has said it's aware of hospitalizations potentially linked to the copycat drugs, but that adverse events are likely being underreported. 'We support the bi-partisan call for the FDA to crack down on counterfeit and illegally sold weight-loss drugs,' said a spokesperson for Hims & Hers Health Inc., one of the telehealth firms that sells compounded GLP-1s. 'We appreciate lawmakers' recognition that legitimate compounded medications dispensed by state-regulated pharmacies are not counterfeit. Patient safety must always come first.' Novo and Lilly have discouraged consumers from using compounded and counterfeit products, including suing telehealth firms that sell the copycat versions and working with border agents to seize illegal shipments. Under the Biden administration, the companies repeatedly urged the FDA to take action, but the agency mostly limited its actions to issuing consumer warnings — even as its top drug official publicly acknowledged safety concerns. Under the Trump administration, the HHS has also focused more heavily on other issues, such as banning food dyes and examining vaccine schedules. Meanwhile, lawmakers are ramping up their calls for action. State attorneys and other lawmakers have sent letters to the FDA and Federal Trade Commission advocating for greater transparency around the treatments and more scrutiny around marketing practices. (Updates with statement from FDA in sixth and seventh paragraphs.) Burning Man Is Burning Through Cash Confessions of a Laptop Farmer: How an American Helped North Korea's Wild Remote Worker Scheme It's Not Just Tokyo and Kyoto: Tourists Descend on Rural Japan Elon Musk's Empire Is Creaking Under the Strain of Elon Musk A Rebel Army Is Building a Rare-Earth Empire on China's Border ©2025 Bloomberg L.P. Sign in to access your portfolio
Yahoo
a minute ago
- Yahoo
Meta names ChatGPT co-creator as chief scientist of Superintelligence Lab
By Echo Wang NEW YORK (Reuters) -Meta Platforms has appointed Shengjia Zhao, co-creator of ChatGPT, as chief scientist of its Superintelligence Lab, CEO Mark Zuckerberg said on Friday, as the company accelerates its push into advanced AI. "In this role, Shengjia will set the research agenda and scientific direction for our new lab working directly with me and Alex," Zuckerberg wrote in a Threads post, referring to Meta's Chief AI Officer Alexandr Wang, who Zuckerberg hired from startup Scale AI when Meta took a big stake in it. Zhao, a former research scientist at OpenAI, co-created ChatGPT, GPT-4 and several of OpenAI's mini models, including 4.1 and o3. He is among several researchers who have moved from OpenAI to Meta in recent weeks, part of a broader talent arms race as Zuckerberg aggressively hires from rivals to close the gap in advanced AI. Meta has been offering some of Silicon Valley's most lucrative pay packages and striking startup deals to attract top researchers, a strategy that follows the underwhelming performance of its Llama 4 model. Meta launched the Superintelligence Lab recently to consolidate work on its Llama models and long‑term artificial general intelligence ambitions. Zhao is a co-founder of the lab, according to the Threads post, which operates separately from FAIR, Meta's established AI research division led by deep learning pioneer Yann LeCun. Zuckerberg has said Meta aims to build 'full general intelligence' and release its work as open source — a strategy that has drawn both praise and concern within the AI community.
Yahoo
a minute ago
- Yahoo
Is Elon Musk to blame for Tesla's struggles? Experts weigh in
Tesla, the electric carmaker led by Elon Musk, suffered a sharp drop in profits over a recent three-month period as car sales slowed and tariffs hiked costs, the company said this week. Shareholders envisioned a different outcome when Tesla stock surged more than 50% in the aftermath of the November 2024 election of President Donald Trump, then a close ally of Musk. Since a recent peak in December, the majority of those gains have been erased. Musk, the company's chief executive and the world's richest person, draws attention due in part to his outspoken presence on social media and divisive stint in the White House. The recent struggles at Tesla have coincided with increased competition in the electric vehicle (EV) industry, posing a question for analysts: Is Musk partially to blame? MORE: Tesla profits drop 16% as Elon Musk faces continued backlash Experts who spoke to ABC News acknowledged the surge of EV competition and credited Musk with pushing the company into potential growth areas like humanoid robots and self-driving taxis, the latter of which are being tested in Austin, Texas. The company's downturn in part reflects a transition from EVs to those new products, which have yet to generate meaningful revenue, they added. Still, the experts said, Musk bears some of the blame for the company's difficulty fending off other EV makers as well as a delayed rollout of alternate products. They also pointed to losses suffered as result of some of Trump's policies, which Musk struggled to mitigate while serving in the administration. "Musk is CEO -- the buck stops with him. As a CEO in a competitive environment, he's the one who has to have the vision and lead the troops," David Meier, a senior investment analyst at The Motley Fool, told ABC News. "But there's a lot going on in the world that impacts Tesla's business." Tesla did not immediately respond to ABC News' request for comment. Speaking on an earnings call on Wednesday, Musk said the company faces "a few rough quarters ahead." He added that, ultimately, humanoid robots and driverless taxis would make Tesla "the most valuable company in the world by far." The company's profits fell 16% over a three-month period ending in June that overlapped with the end of Musk's tenure in the White House and his ensuing public clash with Trump, an earnings release on Wednesday showed. Total revenue decreased by 12% from one year earlier, to $22.4 billion, while revenue derived from car sales dropped 16% over the second quarter of 2025 compared to a year ago, the earnings showed. In a statement, Tesla touted a "strong balance sheet," but acknowledged a "sustained uncertain macroeconomic environment resulting from shifting tariffs." The company also faces "unclear impacts from changes to fiscal policy and political sentiment," Tesla said. The company has faced heightened competition from domestic and foreign carmakers rolling out electric vehicles. Chinese EV-maker BYD outperformed Tesla in total car sales for the first time ever last year. BYD vehicles are essentially unavailable in the U.S. due to sky-high tariffs on Chinese EVs. "Part of it is outside of Tesla's control," Seth Goldstein, an analyst who studies the EV sector at research firm Morningstar, told ABC News. Goldstein cited an apparent dropoff in sales earlier this year among consumers awaiting a refresh of the company's popular Model Y. However, Goldstein added, the company has been slow to release an affordable EV model in response to a flurry of low-cost options among its rivals, which include China's BYD and traditional carmakers like Nissan and Hyundai. "Looking at Elon Musk, he's the leader of Tesla. It's fair to wonder if he was a little distracted with his political action in the first half of the year and that caused some production to slip, including production of an affordable model," Goldstein said. Musk's position at the White House, which ended in May, appeared to yield few benefits for Tesla. The company faces a pinch from several Trump policies, including the end of tax credits for EV buyers, the nixing of regulatory credits purchased from Tesla by other firms, as well as tariffs on cars and car parts. The CEO's political role also set off demonstrations at Tesla dealerships worldwide in protest of his effort to slash government spending as leader of the Department of Government Efficiency (DOGE). "It was a dark chapter and investors are glad to put it in the rear-view mirror," Dan Ives, a managing director of equity research at the investment firm Wedbush and a longtime Tesla bull, told ABC News. As car sales have slowed, Musk has touted a future autonomous car service, dubbed robotaxis, as a growth area for the business. Last month, Tesla launched a limited version of what it claimed is a self-driving taxi service in Austin, Texas. MORE: Trump admin live updates: Trump does not rule out pardon for Maxwell The rollout marked a milestone for the company's self-driving taxi aspirations, but limitations placed on the vehicles and a series of apparent miscues suggest the technology remains far from wide adoption, some analysts previously told ABC News. Musk has also touted humanoid robots as a future growth area for Tesla. While the product remains in an early phase, Musk expects the company to eventually produce more than a million robots each year, he said on this week's earnings call. Goldstein, of Morningstar, applauded Musk's effort to move Tesla away from the highly competitive auto market toward nascent tech sectors. "Musk's long-term goal is to transition from an automaker to an AI robotics company -- that's still on track and making progress," Goldstein said. "That's where it has greater opportunities to grow a competitive advantage." The ultimate outcome for Tesla's forthcoming products remains unclear but Musk has earned the benefit of the doubt, according to some analysts. "It might not be the conventional way but there's only one Elon Musk," Wedbush's Ives said. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
